David Stokesberry, MD
Gastroenterology · Oklahoma City, OKNPI 1427032234
Payments from drug & device makers
Across 482 payments — averaging $3488.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$772K
- Genentech, Inc.$273K
- Bristol Myers Squibb$249K
- Janssen Research & Development, LLC$240K
- Takeda Pharmaceuticals U.S.A., Inc.$67K
- Roche Products Limited$46K
- plus $35K from 26 others
Across 5 payments — averaging $7977.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$40K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 268 | $771,942 |
| Genentech, Inc. | 40 | $272,823 |
| Bristol Myers Squibb | 24 | $248,612 |
| Janssen Research & Development, LLC | 32 | $240,007 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $66,930 |
| Roche Products Limited | 31 | $46,048 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18,749 |
| Boehringer Ingelheim | 2 | $14,745 |
| Janssen Scientific Affairs, LLC | 3 | $269 |
| Johnson & Johnson(2 entities) | 15 | $186 |
| Gilead | 8 | $152 |
| Lilly USA, LLC | 5 | $131 |
| Medtronic | 2 | $108 |
| Madrigal Pharmaceuticals | 4 | $101 |
| Enterra Medical, Inc. | 1 | $80 |
| Celltrion USA Inc. | 3 | $70 |
| Pfizer | 5 | $64 |
| Amgen | 3 | $56 |
| Sanofi | 3 | $53 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Merck | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| QOL Medical, LLC | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 2 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Romark Laboratories, LC | 1 | $1 |
How this compares
$1,681,421 in reported general payments places this provider in the 95th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Oklahoma City
- Tauseef AliOklahoma City$2.1M
- George SalemOklahoma City$1.2M
- Matthew McBrideOklahoma City$741K
- Richard HartyOklahoma City$462K
- Hussein BitarOklahoma City$184K
- Neil CrittendenOklahoma City$143K
- Pooja SinghalOklahoma City$140K
- Trushar PatelOklahoma City$49K
- Sumit WaliaOklahoma City$48K
- Ijlal Akbar AliOklahoma City$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.